Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3)– – Company reducing its workforce by 73% –– Cash and ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

Your trusted source for the latest news delivered weekdays from the team at U.S. News and World Report. Sign in to manage your newsletters » Sign up to receive the latest updates from U.S News ...

IGM Biosciences (NASDAQ:IGMS) announced that it is currently evaluating internal options as well as potential strategic alternatives. Under these changes, it will halt further development of imvotamab ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

Nick Anderson cartoon on alleged ISIS link to the New Orleans attacker.

This advertisement has not loaded yet, but your article continues below.